Souderton, PA., December 6, 2016 – Almac Clinical Technologies, part of the Almac Group, the world’s largest privately-held contract pharmaceutical development and manufacturing organisation, today announced the formation of a strategic partnership with inVentiv Health, a leading biopharma outsourcing company combining a leading CRO and the industry’s only Contract Commercial Organization (CCO). The partnership presents an opportunity for both organisations to provide clients and sites with streamlined access to best-in-class clinical trial Interactive Response Technology (IRT) solutions.
Through the strategic partnership, Almac Clinical Technologies will now provide IRT solutions to inVentiv clients, including its market-leading IXRS® technology. This technology has been used in over 2,000 trials and provides sponsors with the visibility and control needed to make data-driven decisions. inVentiv Health’s IRT specialists will also join Almac Clinical Technologies’ 500+ person expert consultancy team. This team and technology transition will allow Almac and inVentiv to seamlessly service current inVentiv Health IRT clients.
Gregory Skalicky, Chief Commercial Officer, inVentiv Health Clinical Division commented:
“We’re committed to accelerating clinical trials and see tremendous value in applying leading technology solutions to streamline the process. This partnership will enable inVentiv Health to enhance its clinical services continuum by offering clients access to Almac’s comprehensive, best-in-class IRT services to unlock further efficiencies in trial study configuration and deployment.”
inVentiv Health selected Almac as a partner based on Almac’s dedication to customer focus, quality, expertise and innovation. These factors align with inVentiv Health’s commitment to accelerating client success.
Valarie Higgins, President & Managing Director, Almac Clinical Technologies commented:
"This partnership reaffirms Almac’s position as the global leader in clinical technology solutions, like IRT. We’re thrilled to partner with inVentiv Health as their organisational mission aligns seamlessly with the ethos and priorities of the Almac Group. We look forward to our exciting new venture together and the opportunity to offer clients an expanded array of choices to help support the critical work they do every day.”
Almac Clinical Technologies and inVentiv Health will be exhibiting at the 8th annual SCOPE Summit for Clinical Operations Executives on 24-26 of January 2017. Representatives from both organisations will be available to discuss the partnership in greater detail.
About Almac Group
'Partnering to Advance Human Health'
The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has organically grown over 40 years and now employs in excess of 4,500 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in the UK, Ireland, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).
About inVentiv Health
inVentiv Health is a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. Our combined Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) offer a differentiated suite of services, processes and integrated solutions that improve client performance. With more than 15,000 employees and the ability to support clients in 90 countries, our global scale and deep therapeutic expertise enable inVentiv to help clients successfully navigate an increasingly complex environment. For more information, visit inVentivHealth.com.